Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Inclusion Criteria:

- Presence of central retinal vein occlusion (CRVO)

- Age 18 years or older

- ETDRS (Early Treatment Diabetic Retinopathy Study) Visual acuity between 3 and 72
letters and approximate Snellen equivalent of 20/40 to 20/800

- OCT Central foveal thickness >250 microns

- Negative pregnancy test for women of childbearing potential

- Ability to provide written informed consent

- Capable of complying with study protocol

Exclusion Criteria:

- History of glaucoma in the study eye with intraocular pressure >21mmHg on more than
one topical medication. Combination drugs are considered more than one medication

- History of steroid-related glaucoma (steroid response)

- Previous intraocular injection of steroid medication within 90 days

- Avastin (bevacizumab) or Lucentis (ranibizumab) within 60 days

- Evidence of significant retinal ischemia on fluorescein angiography in the opinion of
the treating physician

- Previous intraocular surgery (e.g. Cataract Surgery) with in 60 days

- Concurrent ocular disease that would limit visual acuity in the opinion of the
treating physician

- Dense cataract that precludes clinical examination and retinal imaging of the retina

- History of allergy to dexamethasone, bevacizumab, betadine

- Ocular or systemic conditions that may pose a threat to the health of the subject in
the opinion of the treating physician

- Unwilling or unable to follow or comply with all study related procedures

- Current participation in another clinical medical investigation or trial or has
received any investigational drug within 12 weeks prior to enrollment